CG Oncology (CGON) Institutional Ownership

26.56% of CG Oncology's stock is owned by institutional investors. Learn more on CGON's institutional investor holdings.

Of the 184 institutional investors that purchased CG Oncology's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($7.42M), BlackRock Inc. ($6.26M), Bank of America Corp DE ($2.68M), Foresite Capital Management VI LLC ($2.22M), Price T Rowe Associates Inc. MD ($2.21M), Seven Fleet Capital Management LP ($1.89M), and State Street Corp ($1.67M).

Institutional investors have bought a total of 26,659,226 shares in the last 24 months. This purchase volume represents approximately $1.41B in transactions.

Of the 58 institutional investors that sold CG Oncology's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Braidwell LP ($1.41M), Orbimed Advisors LLC ($1.08M), Bank of America Corp DE ($988.42K), Pictet Asset Management Holding SA ($951.52K), Millennium Management LLC ($706.79K), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($379.45K), and ADAR1 Capital Management LLC ($346.74K).

Institutional investors have sold a total of 8,751,489 shares in the last 24 months. This volume of shares sold represents approximately $432.28M in transactions.